TNF and histiocytic sarcoma: In terms of therapeutic interventions, while systemic antibiotics remain a cornerstone of treatment for HS, particularly in the setting of acute flares and mild-to-moderate disease, the use of biologic agents such as TNFα inhibitors and secukinumab has emerged as a promising option for refractory cases.